Previous close | 17.29 |
Open | 17.20 |
Bid | 17.42 x 800 |
Ask | 17.43 x 1100 |
Day's range | 17.02 - 17.44 |
52-week range | 12.20 - 20.20 |
Volume | |
Avg. volume | 373,863 |
Market cap | 6.024B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | 101.24 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
VAUGHAN, Ontario & TAMPERE, Finland, February 01, 2023--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, and Modulight Corporation ("Modulight"), a biomedical laser company, today announced that the U.S. Food and Drug Administration (FDA) has approved the ML6710i photodynamic laser for equivalent use with Bausch + Lomb’s VISUDYNE® (verteporfin for injection) photodynamic therapy (PDT) for the
VAUGHAN, Ontario, January 23, 2023--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2022 financial results on Wednesday, Feb. 22, 2023. Bausch + Lomb will host a conference call and live web cast at 8:00 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausc
VAUGHAN, Ontario & IRVINE, Calif., January 17, 2023--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, and AcuFocus, Inc. ("AcuFocus"), a privately held ophthalmic medical device company, today announced that an affiliate of Bausch + Lomb has acquired AcuFocus, pursuant to a merger transaction with the parent company of AcuFocus.